Nicaraven

Drug Profile

Nicaraven

Alternative Names: Antevan; Antevas; AVS; CCRIS 7280

Latest Information Update: 07 Nov 2008

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Class Anti-ischaemics; Neuroprotectants; Nicotinic-acids; Nootropics; Small molecules
  • Mechanism of Action Hydroxy radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Subarachnoid haemorrhage

Most Recent Events

  • 31 Jul 2008 Suspended and Withdrawn - Preregistration for Subarachnoid haemorrhage in Japan (IV)
  • 28 Jul 2004 This compound is still in active development for subarachnoidal haemorrhage
  • 31 Dec 2003 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top